Traditional discovery approaches force a trade-off: deep biological resolution for a few perturbations or broad screens with ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

President Anura Kumara Dissanayake while attending the launch of the national operation ‘A Nation United: Eradicating the ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...

FDA designates ZEN-3694 as an orphan drug, offering hope for patients with NUT carcinoma with no current approved therapies. The FDA has granted orphan drug designation to ZEN-3694, a novel oral ...

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...